Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Santhera Explores Strategic Options; Updates Financial Calendar


Print article Print article
Copyright © Thomson Reuters 2013. All rights reserved.
2013-02-28 07:16:27 -

Santhera Pharmaceuticals Holding AG /
Santhera Explores Strategic Options; Updates Financial Calendar
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 


Liestal, Switzerland, February 28, 2013 - Santhera Pharmaceuticals (SIX: SANN)
announced today that following the voluntary withdrawal of Catena(®) from the
Canadian market and the earlier negative decision of the Committee for Medicinal
Products for Human Use (CHMP) on the Market Authorization Application for
Raxone(®) in Leber's Hereditary Optic Neuropathy (LHON), the Board has decided
to consider strategic options including product licensing for Raxone(®) in LHON
and the possibility of a merger or acquisition. Santhera has already received
expressions of interest from third parties and has retained Piper Jaffray
Limited to assist the Company in this process.

The publication of the financial results 
for 2012 will be postponed and, together with the financial outlook for 2013, will now be provided within the timelines required by the SIX regulations. Accordingly, the Company will therefore postpone the Annual Shareholders' Meeting previously planned for April 22, 2013. Shareholders should note that whilst the Board believes that it is in the best interest of shareholders to explore these options and take the steps described, there can be no guarantee that any transaction can be consummated. * * * About Santhera Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan neuromuscular and mitochondrial diseases, areas of high unmet medical need with no current therapies. For further information, please visit www.santhera.com. For further information, contact Thomas Meier, Chief Executive Officer Phone: +41 61 906 89 64 thomas.meier@santhera.com Disclaimer / Forward-looking statements This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements. News release: hugin.info/137261/R/1681770/549895.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Santhera Pharmaceuticals Holding AG via Thomson Reuters ONE [HUG#1681770]


Press Information:




Contact Person:


Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser